Stock Events

Stock Events

Amarin 

$15.86
0
+$0+0% Tuesday 05:51

Statistics

Day High
15.86
Day Low
15.85
52W High
-
52W Low
-
Volume
120
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-35.95%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
457.23MRevenue
-164.37MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMRN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Amarin in the cardiovascular drug market, particularly with drugs aimed at reducing triglyceride levels and improving heart health.
AMGEN
AMGN
Mkt Cap160.66B
Amgen offers a range of cardiovascular treatments that directly compete with Amarin's Vascepa, especially in the high triglyceride management space.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes in the cardiovascular and metabolic disease areas, offering alternative treatments that could be used instead of Amarin's products.
Merck
MRK
Mkt Cap214.76B
Merck & Co. has a portfolio of cardiovascular drugs that can be seen as alternatives to Amarin's offerings, particularly in the lipid management space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of cardiovascular drugs that compete with Amarin, including treatments for conditions that Vascepa is prescribed for.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Amarin in the heart health market, with drugs that offer similar benefits to Vascepa in reducing cardiovascular risk.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its broad portfolio in the pharmaceutical sector, competes in the cardiovascular space, offering treatments that could serve as alternatives to Amarin's products.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a presence in the cardiovascular disease treatment market, competing with Amarin with its range of heart health medications.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, in partnership with Sanofi, develops drugs that compete in the same therapeutic areas as Amarin, including cardiovascular health.

About

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Show more...
CEO
ISIN
US0231114044

Listings

F
DE
EH3.F
BOATS
BOATS
AMRN.BOATS
XNAS
US
AMRN

0 Comments

Share your thoughts

FAQ

What is Amarin stock price today?▼
The current price of AMRN.BOATS is $15.86 USD — it has increased by +0% in the past 24 hours. Watch Amarin stock price performance more closely on the chart.
What is Amarin stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amarin stocks are traded under the ticker AMRN.BOATS.
What is Amarin revenue for the last year?▼
Amarin revenue for the last year amounts to 457.23M USD.
What is Amarin net income for the last year?▼
AMRN.BOATS net income for the last year is -164.37M USD.
When did Amarin complete a stock split?▼
Amarin has not had any recent stock splits.